Mirae Asset Global Investments Co. Ltd. raised its position in shares of Shire PLC (NASDAQ:SHPG) by 341.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,832 shares of the biopharmaceutical company’s stock after buying an additional 18,430 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Shire were worth $4,319,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cornerstone Wealth Management LLC bought a new stake in shares of Shire during the second quarter worth $145,000. CIBC Private Wealth Group LLC lifted its position in shares of Shire by 22.6% during the second quarter. CIBC Private Wealth Group LLC now owns 43,358 shares of the biopharmaceutical company’s stock worth $7,319,000 after purchasing an additional 8,005 shares during the last quarter. Linscomb & Williams Inc. bought a new stake in shares of Shire during the second quarter worth $210,000. Greenleaf Trust lifted its position in shares of Shire by 32.0% during the second quarter. Greenleaf Trust now owns 3,194 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 774 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Shire by 1,634.4% during the second quarter. SG Americas Securities LLC now owns 193,547 shares of the biopharmaceutical company’s stock worth $32,671,000 after purchasing an additional 182,388 shares during the last quarter. 20.49% of the stock is owned by institutional investors.
SHPG has been the subject of several research analyst reports. Sanford C. Bernstein downgraded Shire from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 4th. Royal Bank of Canada set a $195.00 target price on Shire and gave the stock a “buy” rating in a research report on Tuesday, October 23rd. Evercore ISI downgraded Shire from an “outperform” rating to a “market perform” rating and set a $196.00 target price for the company. in a research report on Tuesday, September 4th. ValuEngine upgraded Shire from a “sell” rating to a “hold” rating in a research report on Friday, September 21st. Finally, BidaskClub upgraded Shire from a “sell” rating to a “hold” rating in a research report on Thursday, September 13th. Nine research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Shire currently has an average rating of “Hold” and a consensus price target of $201.11.
Shares of Shire stock opened at $172.75 on Friday. The firm has a market cap of $54.14 billion, a PE ratio of 11.60, a PEG ratio of 1.60 and a beta of 1.01. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.51 and a current ratio of 0.92. Shire PLC has a 12 month low of $123.73 and a 12 month high of $182.47.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 EPS for the quarter, missing the consensus estimate of $3.65 by ($0.01). The firm had revenue of $3.87 billion for the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.81 EPS. Sell-side analysts predict that Shire PLC will post 15.09 earnings per share for the current year.
WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/12/08/shire-plc-shpg-stake-increased-by-mirae-asset-global-investments-co-ltd.html.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Featured Article: Bear Market – How and Why They Occur
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.